Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C32H42Cl2N4O3 |
| Molecular Weight | 601.607 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)C1(CCN(CC[C@]2(CN(CCO2)C(=O)C3=CC=CC=C3)C4=CC(Cl)=C(Cl)C=C4)CC1)N5CCCCC5
InChI
InChIKey=RVQZVVJLIUXDPN-YTTGMZPUSA-N
InChI=1S/C32H42Cl2N4O3/c1-35(2)30(40)31(38-16-7-4-8-17-38)13-18-36(19-14-31)20-15-32(26-11-12-27(33)28(34)23-26)24-37(21-22-41-32)29(39)25-9-5-3-6-10-25/h3,5-6,9-12,23H,4,7-8,13-22,24H2,1-2H3/t32-/m0/s1
| Molecular Formula | C32H42Cl2N4O3 |
| Molecular Weight | 601.607 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:48:30 GMT 2023
by
admin
on
Sat Dec 16 10:48:30 GMT 2023
|
| Record UNII |
A5ZU7GBJ9Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
46919619
Created by
admin on Sat Dec 16 10:48:30 GMT 2023 , Edited by admin on Sat Dec 16 10:48:30 GMT 2023
|
PRIMARY | |||
|
DTXSID70891361
Created by
admin on Sat Dec 16 10:48:30 GMT 2023 , Edited by admin on Sat Dec 16 10:48:30 GMT 2023
|
PRIMARY | |||
|
1239279-30-1
Created by
admin on Sat Dec 16 10:48:30 GMT 2023 , Edited by admin on Sat Dec 16 10:48:30 GMT 2023
|
PRIMARY | |||
|
300000042487
Created by
admin on Sat Dec 16 10:48:30 GMT 2023 , Edited by admin on Sat Dec 16 10:48:30 GMT 2023
|
PRIMARY | |||
|
A5ZU7GBJ9Y
Created by
admin on Sat Dec 16 10:48:30 GMT 2023 , Edited by admin on Sat Dec 16 10:48:30 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
RACEMATE -> ENANTIOMER |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
The GLY-T1 reuptake pump is the major route of inactivation of synaptic glycine (Figure 1), so it is logical to explore the ability of GLY-T1 inhibitors to enhance synaptic actions of glycine, and, thus, of NMDA receptors (Figure 4). Several GLY-T1 inhibitors are now in testing, including the natural agent N-methyl-glycine, also known as sarcosine, as well as drugs in preclinical testing, such as SSR 504734, SSR 241586, JNJ17305600, and Org 25935. GLY-T1 inhibitors are analogous to drugs that inhibit reuptake of other neurotransmitters, such as the serotonin selective reuptake inhibitors and their actions at the serotonin transporter. When GLY-T1 pumps are blocked by a GLY-T1 inhibitor, this increases the synaptic availability of glycine, and thus enhances NMDA neurotransmission.
|
||
|
ACTIVE MOIETY |
SSR 241586 is a 2,2-disubstituted morpholine, developed by Sanofi-Aventis, which is active in the treatment of schizophrenia and irritable bowel syndrome (IBS). Different strategies have been studied to synthesize this molecule and among the strategies an organo-catalyzed Henry reaction, applied to an .ALPHA.-keto ester, has produced SSR 241586 in excellent enantiomeric excess.
|
||
|
ACTIVE MOIETY |
Class: Antidepressant, Antipsychotic, Anxiolytic and Irritable bowel syndrome therapy; Mechanism of Action: Neurokinin 2 receptor antagonist and Neurokinin 3 receptor antagonist; Highest Development Phases: Discontinued for Anxiety disorders, Irritable bowel syndrome, Major depressive disorder and Schizophrenia; Most Recent Events: 17 Sep 2007 Phase-I clinical trials in Schizophrenia in France (unspecified route), 17 Sep 2007 Phase-I clinical trials in Irritable bowel syndrome in France (unspecified route), 17 Sep 2007 Phase-I clinical trials in Depression in France (unspecified route)
|
